Stada Arzneimittel AG is poised to enhance its consumer healthcare portfolio in both developed and developing European markets by acquiring from GlaxoSmithKline PLC a basket of 15 brands, mainly in the cold & flu, pain and skin-care categories. The transaction is expected to close in the second quarter of 2020.
While the value of the deal has not been disclosed, a spokesperson for Stada told HBW Insight that combined annual sales of the
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?